FDA Approval
The FDA has approved Novo Nordisk's Wegovy pill, marking it as the first oral GLP-1 medication for weight loss in adults. This approval introduces a new option for obesity treatment in the U.S.
Clinical Trial Results
In the OASIS 4 trial, Wegovy tablets demonstrated an average weight loss of approximately 17% for patients who remained on treatment. The weight loss was around 14% regardless of treatment adherence.
Availability and Pricing
The Wegovy pill will be available starting in early January, with a 1.5 mg starting dose priced at $149 per month, including savings offers. The pill is produced in the U.S., with a robust supply ready for distribution.
Cardiovascular Benefits
Wegovy is the only GLP-1 medication indicated for weight loss that also helps prevent major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, alongside diet and exercise.
